secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001104659-23-087630
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec Q2 PEDMARK revenue $3.3M, up 98% QoQ; appoints Adrian Haigh as COO
-------------------------------------------------------------------------

- Net product sales of PEDMARK $3.3M, a 98% sequential increase from Q1 2023.
- Net loss of $5.4M ($0.21/share) vs $5.1M ($0.19/share) in Q2 2022.
- Cash and equivalents $15.0M; management says sufficient for at least 12 months.
- Appointed Adrian Haigh as COO; he steps down from the board of directors.
- Management to present at Wedbush PacGrow Healthcare Conference on August 8-9, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923087630/0001104659-23-087630-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923087630/tm2322902d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-087630

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer